Nevertheless, a limitation of this study is the single-arm and open-label design, which does not include a direct comparison with a control group. Furthermore, as the study design focused on real-world evidence, the use of concomitant medications was permitted, apart from other types of decongestants. Therefore, some of the observed symptomatic improvements may not be solely due to treatment with the study drug. Additionally, as the common cold is a self-limiting disease, it is also important to delineate which symptomatic improvements can be attributed to the effectiveness of xylometazoline hydrochloride 0.1% treatment, compared with symptomatic resolution during the natural course of disease.